<DOC>
	<DOCNO>NCT01124565</DOCNO>
	<brief_summary>This study 's objective evaluate RT001 safe well-tolerated follow two ( 2 ) sequential application .</brief_summary>
	<brief_title>Safety Study Two Repeat Doses RT001 Treatment Moderate Severe Lateral Canthal Lines Adults</brief_title>
	<detailed_description>Revance conduct Phase 2 clinical study establish safety two ( 2 ) sequential dos RT001 Topical Gel Baseline ( Day 0 ) Week 4 treatment moderate severe LCLs rest .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<criteria>Written inform consent include authorization release health information Female male , 18 65 year age good general health Willing able follow study instruction likely complete study requirement Moderate severe lateral canthal line ( crow 's foot wrinkle ) Any neurological condition may place subject increase risk exposure Botulinum Toxin Type A , include peripheral motor neuropathic disease amyotrophic lateral sclerosis motor neuropathy , neuromuscular junctional disorder LambertEaton syndrome myasthenia gravis Muscle weakness paralysis , particularly area receive study treatment Active disease irritation treatment area include eye skin Pregnant , nursing , plan pregnancy study ; woman child bear potential ( WOCBP ) willing use effective method birth control Previous participation RT001 clinical study Previous treatment botulinum toxin ( serotype )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Lateral Canthal Lines</keyword>
	<keyword>Crow 's Feet</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>